NanoPhoria bioscience
Milan, Italy · nanophoria.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
NanoPhoria bioscience is a preclinical-stage biotechnology company developing cardiovascular therapeutics. It focuses on inhaled nano-in-micro drug delivery for heart failure with reduced ejection fraction and works from sites in Milan and Faenza, Italy.
They take quote requests by email.
What they offer
Drug delivery platform development
Develops a proprietary Nano-in-Micro platform built on inorganic calcium phosphate nanoparticles for inhalation and other administration routes.
Peptide therapeutics development
Develops mimetic peptide therapeutics intended to restore cardiac function in cardiomyocytes.
Oligonucleotide therapeutics development
Develops oligonucleotide-based therapeutics designed to regulate disease-driving pathways in cardiomyocytes.
Pipeline development for NP-MP1
Advances NP-MP1 as an inhalable Nano-in-Micro formulation delivering a calcium channel modulator peptide for HFrEF.
Preclinical proof-of-concept research
Generates proof-of-concept evidence that the Nano-in-Micro platform can deliver therapeutic peptides to cardiomyocytes.
Scientific publishing and translational research
Translates cardiovascular biology and materials science research into evidence-led therapeutic platform development.
What they work on
- Modalities
- Antibody, ADC, Peptide, Oligonucleotide
- Species and models
- cardiomyocytes, pig models
- Therapeutic areas
- cardiovascular disease, heart failure with reduced ejection fraction (HFrEF)
- Sites
- Milan, Italy · Faenza (Ravenna), Italy
- Founded
- 2022
Similar labs. AlphaThera, Aurigene Pharmaceutical Services, Transcenta Holding, Veloxity Labs
Found in a contract services directory. Listing built from nanophoria.com. Work here? Claim this listing.